Infliximab in Takayasu arteritis: a safe alternative?

Clin Rheumatol. 2007 Jun;26(6):984-7. doi: 10.1007/s10067-006-0227-0. Epub 2006 Apr 22.


Objective: To test the efficacy of Infliximab, a chimeric monoclonal antibody against TNF-alpha, in the treatment of Takayasu arteritis.

Materials and methods: We used infliximab at an initial dose of 3 mg/kg i.v. at weeks 0, 2, 6, and 8 thereafter in combination with methotrexate or azathioprine, to treat four patients with Takayasu arteritis.

Results: Three out of four patients responded to infliximab treatment, while two of them retained the response during a two-year follow up. A higher dose regimen (5 mg/kg), however, was eventually warranted for two of the responders. No major side effects were noted.

Conclusions: Infliximab might be an effective and safe alternative for patients with Takayasu arteritis.

Publication types

  • Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Antirheumatic Agents / adverse effects
  • Antirheumatic Agents / therapeutic use*
  • Female
  • Follow-Up Studies
  • Humans
  • Infliximab
  • Takayasu Arteritis / drug therapy*
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / adverse effects
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*


  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Tumor Necrosis Factor-alpha
  • Infliximab